Lv5
1070 积分 2021-09-15 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
7天前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
20天前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
20天前
已完结
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
20天前
已完结
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study
20天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
22天前
已完结
Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression
1个月前
已完结
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
1个月前
已完结
Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study
2个月前
已完结
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308
